OSE Immunotherapeutics Says Tedopi Combinations Meet Primary Endpoint in Phase 2 Lung Cancer Trial

• OSE Immunotherapeutics reported positive final Phase 2 Combi-TED results for Tedopi combinations in metastatic non-small cell lung cancer.
• Results were presented October 25, 2026, at the European Society for Medical Oncology annual meeting in Madrid.
• Both combinations met the primary survival endpoint; survival outcomes favored Tedopi with docetaxel or nivolumab over docetaxel alone.
• Exploratory analyses favored the combinations but fell short of the predefined threshold for advancing to Phase 3; no unexpected safety signals emerged.
• The ongoing ARTEMIA Phase 3 trial is evaluating Tedopi alone against docetaxel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291330OMX_____CNEWS_EN_GNW1001280741_en) on October 29, 2026, and is solely responsible for the information contained therein.